GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Cyclically Adjusted Price-to-FCF

Lattice Biologics (TSXV:LBL.H) Cyclically Adjusted Price-to-FCF : (As of Jun. 11, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lattice Biologics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Lattice Biologics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Cyclically Adjusted Price-to-FCF Chart

Lattice Biologics Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Sep16 Sep17 Sep18 Sep19 Sep20
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lattice Biologics Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lattice Biologics's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Lattice Biologics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lattice Biologics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lattice Biologics's Cyclically Adjusted Price-to-FCF falls into.



Lattice Biologics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Lattice Biologics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2021 is calculated as:

For example, Lattice Biologics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2021 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2021 (Change)*Current CPI (Jun. 2021)
=0/114.6314*114.6314
=0.000

Current CPI (Jun. 2021) = 114.6314.

Lattice Biologics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201109 -0.050 95.727 -0.060
201112 -0.054 95.213 -0.065
201203 -0.047 96.783 -0.056
201206 -0.025 96.819 -0.030
201209 0.004 97.633 0.005
201212 -0.003 96.871 -0.004
201303 0.000 98.209 0.000
201306 -0.001 98.518 -0.001
201309 0.000 98.790 0.000
201312 -0.035 98.326 -0.041
201403 -0.013 99.695 -0.015
201406 -0.002 100.560 -0.002
201409 -0.003 100.428 -0.003
201412 0.003 99.070 0.003
201503 -0.001 99.621 -0.001
201506 -0.003 100.684 -0.003
201509 -0.987 100.392 -1.127
201512 -0.106 99.792 -0.122
201603 -0.006 100.470 -0.007
201606 -0.017 101.688 -0.019
201609 -0.012 101.861 -0.014
201612 -0.011 101.863 -0.012
201703 -0.004 102.862 -0.004
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.002 107.251 0.002
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 -0.001 109.815 -0.001
202012 -0.001 109.897 -0.001
202103 -0.005 111.754 -0.005
202106 0.000 114.631 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lattice Biologics  (TSXV:LBL.H) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Lattice Biologics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Lattice Biologics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lattice Biologics (TSXV:LBL.H) Business Description

Traded in Other Exchanges
N/A
Address
512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines